

RSC Applied Interfaces


GOLD
OPEN
ACCESS

Interfacial and surface research
with an applied focus

Interdisciplinary and open access

rsc.li/RSCApplInter

Fundamental questions
Elemental answers



Showcasing research from Dr Aron Blaesi's group at Enzian Pharmaceuticals, Zurich, Switzerland and Cambridge, MA, USA.

Enhancing the bioavailability of sparingly-soluble drugs by expandable, solid-solution fibrous dosage forms

At present, the effectiveness of many life-saving oral therapies employing a sparingly water-soluble drug is limited by the drug's bioavailability. For enhancing bioavailability, Blaesi's group at Enzian Pharmaceuticals has developed an expandable, solid-solution fibrous dosage form. The fibrous form releases drug into the stomach at a high rate for prolonged time. In dogs it enhanced the bioavailability of the sparingly-soluble model drug nilotinib three-fold compared with the present crystalline drug particle-filled capsules.

Image reproduced by permission of Aron H Blaesi, Enzian Pharmaceuticals Blaesi AG from *RSC Pharm.*, 2026, **3**, 88.

As featured in:



See Aron H. Blaesi *et al.*, *RSC Pharm.*, 2026, **3**, 88.